Corvus Pharmaceuticals Inc (CRVS)

[flatlander_60048]

Upcoming Catalysts for CRVS.

1) AACR presentation on 818 in Mid April;
2) ICML presentation in Lugano in Mid June;
3) Top Line data on ongoing Angel Phama trials in China;
4) Meeting with FDA to design the 818 Phase 3 Registrational trial;
5) Announcement of a Big Pharma partner for Clinical Trials??????

Any others I'm missing. For some reason Yahoo blocks this content.

FL

[flatlander_60048]

The situation you describe is pretty common with a lot of innovative types. I agree that the focus seems to be constantly shifting. Remember 006 use for Covid? I think focusing on 818 use for T-Cell Lymphoma is the right target. The SOC (chemo) has a miserable PFS rate and it tears down the immune system. So a positive registration trialfor 818 has the potential to launch a front line treatment before the patients immune system and ACL threshold is decimated. CRVS needs to execute a positive mtg with FDA and land a decent partnership. If Miller is correct and 818 has application for solid tumors, immune disorders, etc., the licensing of one indication to bring in the cash infusion will be seen as well worth it.

Hopefully others from Yahoo board follow. Not sure what business model they are following but the dissatisfaction level is off the charts.

Regards FL.

[kenyonn2000]

Agree 100%. No arguing over Mille's scientific chops, or the credentials of the board. But I have concerns over his business abilities. He nearly ran Pharmacyclics into the ground before Duggan stepped in and forced him out. We'll never know if he might have turned that around or not, but you can't put that massive success story on Miller. So, can he deliver from a business perspective? In my opinion, Corvus has been all over the place since it's founding--one promise after another abruptly abandoned. 818 looks like the real deal and could be a massive blockbuster--but we are walking the tightrope here with funding, no room for error anymore.

[flatlander_60048]

Yes, I am a CRVS holder. Yahoo is having problems censoring posts, so I have suggested that the posters jump to IHUB. I've also posted on Biotech values.

I like the science at CRVS and love Millers track record, but I can't shake the feeling that he may be trying to pull a rabbit from the hat when his back is to the wall. A lot is riding on his upcoming meeting with the FDA.

FL

[kenyonn2000]

Looking to revive interest in this board. Any Corvus holders out there?

[diversified holdings]

Could shoot to $4,6 or 8 a share very quickly.

[diversified holdings]

Looking for a nice run here. Setting up nicely!

[diversified holdings]

Wow, 4 month of no posts to the board. Chart is primed for a reversal here.

[BooDog]

Volume kicked in late in the day, nice push!

No position. Was busy with leaves, just a few billion more to bag up.

[BooDog]

Watching closer. 3.28

Still a gap to fill around 2.25, one thing I hate is gaps. They almost always fill. But, will they be able to hold this one up?


https://finviz.com/quote.ashx?t=crvs

[gene_genome]

Could be a conspiracy..

[gene_genome]

News leak..News leak..

[BooDog]

And the selling continues as I thought it would. Taking advantage of over pricing is just a natural thing imo. Once this is back around 2.50 - 3 I think we'll see them getting their shares back. I will be anyway. But then, if they showed constraint 1.e. patience (not selling), it would show a lot more faith in their own science.

https://ih.advfn.com/stock-market/NASDAQ/corvus-pharmaceuticals-CRVS/stock-news/86197328/statement-of-changes-in-beneficial-ownership-4

[BooDog]

Thinking this is the reset many have been waiting for. Like maybe filling the gap in the 2.40's.

[masterofdisaster]

Nice rip

[masterofdisaster]

There Is more to this story that none of us know.

[gene_genome]

From this week's Barron's..pg M7..

[gene_genome]

OrbiMed Advisors lowered its position in the biopharmaceutical company to 6,943,654 shares. Without citing a reason, OrbiMed sold 1,109,644 Corvus Pharmaceuticals shares on Sept. 20 at prices ranging from $6.01 to $6.09 per share. After the sale, OrbiMed now owns 16.4% of Corvus Pharmaceuticals’ tradable stock. Shares have rallied in recent days, and OrbiMed was selling at prices that were more than twice the previous week’s trading level.

[masterofdisaster]

Heavy shorting. The last 3 trading sessions have been the same. Give it some time CRVS will fly.

[Roadtojourney]

Theres more buys then sell yet this is down?? Why??

[masterofdisaster]

CRVS is not dead

[masterofdisaster]

Did you see the amount of large buys yesterday? There has to be something going on behind the sceens

[masterofdisaster]

Good info thank you

[BooDog]

Here's their form 13 showing what they have left. I have to admit I took advantage of the push up as well though I didn't have the patience (or even the slightest idea) this would go as high as it did. I am watching to build back in though not at the current levels. And if a major deal comes thru in the meantime, well, good for those riding the dip/reset!

Peter Thompson, M.D., a member of our Board of Directors since November 2014, is a Private Equity Partner at OrbiMed Advisors, LLC.
https://www.sec.gov/Archives/edgar/data/1055951/000094787121001015/ss504879_sc13da.htm

Tang form 13
Tang form 13

CRVS Institutional holdings



Thinking we may see more form 13's taking advantage, but that's just my guess.

[masterofdisaster]

That was an institutional sale at market not an insider.

[masterofdisaster]

Not a good sign

[BooDog]

Insiders taking advantage of the surge...
https://ih.advfn.com/stock-market/NASDAQ/corvus-pharmaceuticals-CRVS/stock-news/86116048/statement-of-changes-in-beneficial-ownership-4

Thinking we may see a few more form 4's.


So what
Corvus is currently testing mupadolimab as both a monotherapy and as part of a combination treatment in two early-stage trials for various solid tumors. Investors, for their part, seem to think that this experimental CD73 antibody might attract either a lucrative licensing deal or perhaps a full-on buyout in the wake of Astra's impressive midstage trial results. Now, the interesting part of this story is that this hypothesis could actually have some truth behind it. Big pharma has shown a keen interest in early-stage oncology assets of late, especially ones with a novel mechanism of action such as mupadolimab.

Now what
Is Corvus stock worth buying on this pullback? While speculative, this small-cap biotech may indeed be worth the risk. Astra, and several other big pharmas, have long been on the hunt for agents to boost the efficacy of their checkpoint inhibitors in several hard-to-treat cancers. So it wouldn't be surprising in the least if one or more of these pharma giants approached Corvus about a partnership soon.

That being said, there are no guarantees that a deal will materialize, meaning that investors may want to keep their starter position on the small side for the time being.
https://www.fool.com/investing/2021/09/22/why-corvus-pharmaceuticals-stock-is-down-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article

[jxphilli]

For anyone that doesn't know, this is outrageous for a red day. Just an FYI

[jxphilli]

Good to go. Numbers line up. My bookmark moved was my issue. Minor IT setback lol thanks Master !

[masterofdisaster]

Today's volume numbers
Total volume= 14,483,940 shares
Short exempts = 567,322 shares
Short volume= 9,440,424 shares

65% of today's volume was short and we only drop to the $7.40s.

We are going higher.

[masterofdisaster]

Did you see order flow distribution for today?

[masterofdisaster]

4.2 million short exempts in the last 4 trading sessions. What is their plan

[masterofdisaster]

550,000 short exempts today on a day where buy greatly out did sells. This will be a beast some time soon

[masterofdisaster]

Shorts wasted their time shorting this today

[jxphilli]

There's no way this should be red. Fukery at its best. How much are they paying to borrow shares under the table lol

[masterofdisaster]

LET THIS SINK IN ABOUT TODAYS TRADING

[masterofdisaster]

Shorts went to town today!!! You need to look at the order flow distribution!!!!

[masterofdisaster]

MMs have taken the day off and let the shorts have their way. CRVS is hold up very well today.

[masterofdisaster]

CRVS is holding up well today.

[gene_genome]

Corvus Pharmaceuticals Provides Updates on Mupadolimab (Anti-CD73) Programs in Oncology and Infectious Disease..

[gene_genome]

Tang Capital Partners Lp Reports 8.8% Passive Stake In Corvus Pharmaceuticals Inc..

[masterofdisaster]

Holding up well. The last 2 days we saw volume spike right about now. We shall see

[masterofdisaster]

Daily short exempt numbers are ridiculous

[masterofdisaster]

Some think it is for the cancer treatment

[Surfacetite]

is this good?

[masterofdisaster]

25,000 available now

[masterofdisaster]

50,000 available. A small fraction of what the MMs need

[masterofdisaster]

85,000 shares available on fintel at a very low rate. Been zero shares for days an IBK keeps the rate low to get people to use them and then raises the rates drastically.
Been some covering

[masterofdisaster]

I think today is going to be wild as f@ck. Buckle up for the ride

[masterofdisaster]

Thanks for the info